180 Life Sciences Corp. Retains Senior Technology Consultant and Commences Gaming Technology Platform Integration

Rhea-AI Summary

180 Life Sciences Corp (NASDAQ:ATNF) has announced the appointment of Vaclav Vincalek as Senior Technology Consultant to oversee the integration of their recently acquired Gaming Technology Platform. Vincalek, an experienced technologist with expertise in technical leadership and strategy, will work with management to establish the company's online gaming infrastructure. This strategic move represents the company's effort to expand its presence in the gaming industry and enhance its technological capabilities. The integration is expected to strengthen the company's infrastructure and create new growth opportunities.

Positive

• Strategic acquisition of Gaming Technology Platform
• Recruitment of experienced technology consultant for platform integration

Negative

• None.

Insights

Tech Expert

The hiring of a technology consultant and commencement of gaming platform integration represents a significant pivot for 180 Life Sciences, traditionally focused on biotechnology. The company appears to be undergoing a major strategic shift into the gaming sector, which raises concerns about focus and execution risk. The lack of clear monetization details, specific platform capabilities, or financial projections makes it difficult to assess the potential impact on shareholder value. While gaming technology could offer new revenue streams, this dramatic departure from the company's core business model introduces substantial uncertainty and operational challenges. The absence of concrete timelines, market strategy, or competitive analysis further compounds the speculative nature of this transition.

PALO ALTO, CA / ACCESSWIRE / October 31, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF) today announced the retention of Mr. Vaclav Vincalek as Senior Technology Consultant. An accomplished technologist with a strong record in technical leadership and strategy, Mr. Vincalek has guided numerous software businesses in areas of team development, technology systems architecture, and stakeholder communication.

Mr. Vincalek will work closely with management to oversee the onboarding of the recently acquired Gaming Technology Platform. Commencing this integration process marks a significant step forward in the Company's efforts to establish a robust online gaming infrastructure.

With the addition Mr. Vincalek's expertise in technology strategy, 180 continues to take measures to position itself as a leader in innovative solutions across diverse technology sectors. This strategic move underscores the Company's commitment to enhancing its capabilities and expanding its offerings within the rapidly evolving gaming industry.

"We are thrilled to welcome Mr. Vincalek to our team," said Mr. Jordan, Interim CEO of 180, who continued, "His expertise will be instrumental in the successful integration of our Gaming Technology Platform, and we believe his guidance will enable us to maximize the platform's potential."

The Company looks forward to leveraging Mr. Vincalek's extensive knowledge in technology integration and architecture to accelerate the development and deployment of its gaming initiatives. The integration is anticipated to not only strengthen 180's technological infrastructure but also open new avenues for growth and value creation.

About 180 Life Sciences Corp.

180 Life Sciences Corp. is an innovative biotechnology company that is focused on advancing breakthrough treatments. With recent moves into the online gaming sector, the Company is leveraging its expertise and new strategic appointments to capitalize on the expanding opportunities in this market.

Forward-Looking Statements

This press release includes "forward-looking statements", including information about management's view of the Company's future expectations, plans and prospects, within the safe harbor provisions provided under federal securities laws, including under The Private Securities Litigation Reform Act of 1995 (the "Act"). Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results and, consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements and factors that may cause such differences include, without limitation, the ability of the Company to maintain the continued listing of the Company's securities on The Nasdaq Stock Market, including that the Company is not currently in compliance with Nasdaq's continued listing standards due to its current failure to maintain a three person audit committee and/or a majority of independent directors; the Company's ability to raise funding to support its operations and commercialize its newly acquired Gaming Technology Platform; the Company's ability to commercialize its Gaming Technology Platform; the lack of experience of current management with operating a gaming company; the ability of the Company to build out or acquire a front end for the Gaming Technology Platform, and the costs and timing associated therewith; the ability of the Company to generate revenue from the Gaming Technology Platform, including timing and cost thereof; our need for significant additional funding, the ability of the Company to raise funding, the terms of such funding, and dilution caused thereby; competition in the iGaming industry; risks relating to fraud, theft or cheating; our ability to obtain and maintain licenses, and the terms thereof; our required reliance on third party cloud service providers and providers of third-party communications infrastructure, hardware and software; the review and evaluation of strategic transactions and their impact on shareholder value; the process by which the Company engages in evaluation of strategic transactions; the outcome of potential future strategic transactions and the terms thereof; our ability to commercialize our drug candidates, if proven successful for treatment in trials; risks regarding whether the administrative processes required for the issuance of patents will be completed in a timely manner or at all; risks regarding the outcome of pharmaceutical studies, the timing and costs thereof, and the ability to obtain sufficient participants; the timing of, outcome of, and results of, clinical trials statements regarding the timing of marketing authorization application (MAA) submissions to the UK Medicines and Healthcare products Regulatory Agency (MHRA) and New Drug Application submissions (NDA) to the U.S. Food and Drug Administration (FDA), our ability to obtain approval and acceptance thereof, the willingness of the MHRA to review such MAA and the FDA to review such NDA, and our ability to address outstanding comments and questions from the MHRA and FDA; statements about the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the uncertainties associated with the clinical development and regulatory approval of 180's drug candidates, including potential delays in the enrollment and completion of clinical trials, the costs thereof, closures of such trials prior to enrolling sufficient participants in connection therewith, issues raised by the FDA, the MHRA and the European Medicines Agency (EMA); the ability of the Company to persuade regulators that chosen endpoints do not require further validation; timing and costs to complete required studies and trials, and timing to obtain governmental approvals; 180's reliance on third parties to conduct its clinical trials, enroll patients, and manufacture its preclinical and clinical drug supplies; the ability to come to mutually agreeable terms with such third parties and partners, and the terms of such agreements; estimates of patient populations for 180's planned products; 180's ability to fully comply with numerous federal, state and local laws and regulatory requirements, as well as rules and regulations outside the United States; current negative operating cash flows and a need for additional funding to finance our operating plans; the terms of any further financing, which may be highly dilutive and may include onerous terms, increases in interest rates which may make borrowing more expensive and increased inflation which may negatively affect costs, expenses and returns; statements relating to expectations regarding future agreements relating to the supply of materials and license and commercialization of products; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations; expectations with respect to future performance, growth and anticipated acquisitions; expectations regarding the capitalization, resources and ownership structure of the Company; the ability of the Company to execute its plans to develop and market products and the timing and costs of these programs; estimates of the size of the markets for the Company's planned products; the outcome of current litigation involving the Company; potential future litigation involving the Company or the validity or enforceability of the intellectual property of the Company or lawsuits alleging that we have violated the intellectual property of others; global economic conditions; geopolitical events and regulatory changes; and the effect of changing interest rates and inflation, economic downturns and recessions, declines in economic activity or global conflicts.

These risk factors and others are included from time to time in documents the Company files with the Securities and Exchange Commission, including, but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks, and including the Annual Report on Form 10-K for the year ended December 31, 2023, and Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, and future SEC filings. These reports and filings are available at www.sec.gov and are available for download, free of charge, soon after such reports are filed with or furnished to the SEC, on the "Investors", "SEC Filings", "All SEC Filings" page of our website at www.180lifesciences.com. All subsequent written and oral forward-looking statements concerning the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, including the forward-looking statements included in this press release, which are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as otherwise provided by law.

Investor Contact:
Blair Jordan
Interim Chief Executive Officer
Email address: bjordan@180lifesciences.com

SOURCE: 180 Life Sciences Corp.

View the original press release on accesswire.com

FAQ

Who did 180 Life Sciences (ATNF) hire as Senior Technology Consultant?

180 Life Sciences hired Vaclav Vincalek as Senior Technology Consultant to oversee the integration of their Gaming Technology Platform.

What is the purpose of ATNF's Gaming Technology Platform integration?

The integration aims to establish a robust online gaming infrastructure, strengthen technological capabilities, and create new growth opportunities for the company.

What is 180 Life Sciences' (ATNF) latest strategic move in the gaming industry?

ATNF has begun integrating their recently acquired Gaming Technology Platform and hired Vaclav Vincalek as Senior Technology Consultant to oversee the process.